Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab.
10.3904/kjm.2017.92.4.415
- Author:
Joohyun HONG
1
;
Joohwan BAE
;
Sang geul LEE
;
Mingi LIM
;
Young Hye KO
;
Seok Jin KIM
;
Won Seog KIM
Author Information
1. Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wonseog.kim@samsung.com
- Publication Type:Case Report
- Keywords:
Hodgkin disease;
Pembrolizumab
- MeSH:
Adolescent;
Drug Therapy;
Electrons;
Fever;
Hodgkin Disease*;
Humans;
Male;
Positron-Emission Tomography and Computed Tomography;
Prognosis;
Radiotherapy
- From:Korean Journal of Medicine
2017;92(4):415-418
- CountryRepublic of Korea
- Language:English
-
Abstract:
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regimens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pembrolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprogression in patients treated with pembrolizumab.
